Halozyme Therapeutics (HALO) 9.80 $HALO
Halozyme's PEGPH20 Study S1313 Clinical Hold Lifted by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 46 mins ago
The FDA has lifted the clinical hold from a phase II study on Halozyme's (HALO) PEGPH20 in combination with modified FOLFIRINOX for advanced pancreatic cancer, which is being conducted by SWOG.
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:39AM CDT
Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day.
SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer
PR Newswire - Thu Sep 18, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313). The trial is designed to evaluate Halozyme's investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma. The study will resume under a revised protocol, and patient enrollment is anticipated to recommence upon review and approval of the amended protocol by the Independent Review Boards at the participating clinical trial sites.
Nasdaq stocks posting largest percentage increases
AP - Wed Sep 17, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
5 Stocks With Big Insider Buying
at The Street - Wed Sep 17, 11:28AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
Biotech Stocks in Motion - XOMA, Nanosphere, Isis Pharma, Halozyme Therapeutics, and Synta Pharma
PR Newswire - Wed Sep 17, 7:45AM CDT
The US markets on Tuesday, September 16, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,131.97, up 0.59% and the NASDAQ Composite closed at 4,552.76, up 0.75%. The S&P 500 finished the session 0.75% higher at 1,998.98. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index gaining 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: XOMA Corporation (NASDAQ: XOMA), Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at:
Baxter and Halozyme Therapeutics Get FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 12:50PM CDT
Baxter International (BAX) expects to launch HYQVIA in the U.S. in a few weeks.
FDA Approves Baxter's HYQVIA for Treatment of Adu
M2 - Mon Sep 15, 10:10AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary Immunodeficiency
M2 - Mon Sep 15, 9:55AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
KRE, XME, XES, HALO, MLNX, GMM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 11, 4:27AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPDR S&P Regional Banking ETF (NYSE:KRE), Xmet Inc (NYSE:XME), SPDR S&P Oil & Gas Equipment & Services ETF (NYSE:XES), Halozyme Therapeutics Inc (NASDAQ:HALO), Mellanox Technologies Ltd (NASDAQ:MLNX), SPDR S&P Emerging Markets ETF (NYSE:GMM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Why You Shouldn't Bet Against Halozyme Therapeutics (HALO) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:42AM CDT
Halozyme Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
Halozyme's PEGPH20 Program Gains Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:00PM CDT
Earlier this week, Halozyme Therapeutics' (HALO) got some good news with the FDA granting fast track designation to the PEGPH20 (PEGylated recombinant human hyaluronidase) program.
Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation
PR Newswire - Wed Sep 03, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer to demonstrate an improvement in overall survival. The Fast Track designation process was developed by the FDA to facilitate the development, and expedite the review of drugs to treat serious or life-threatening diseases and address unmet medical needs.
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.
Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Pharma, Synta Pharma, Halozyme Therapeutics, and Isis Pharma
PR Newswire - Thu Aug 14, 8:30AM CDT
On Wednesday, August 13, 2014, the NASDAQ Composite ended at 4,434.13, up 1.02%, the Dow Jones Industrial Average finished the day 0.55% higher at 16,651.80, and the S&P 500 closed at 1,946.72, up 0.67%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.08, up 1.15%, with the index also advancing 4.55% in the previous three months. Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at:
Intercept Pharma Soars On Positive Liver Drug Data
at Investor's Business Daily - Mon Aug 11, 9:20PM CDT
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market...
Halozyme to Host second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Aug 04, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2014.
FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency
M2 - Mon Aug 04, 6:32AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.
Halozyme's PEGPH20 Study S1313 Clinical Hold Lifted by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 46 mins ago
The FDA has lifted the clinical hold from a phase II study on Halozyme's (HALO) PEGPH20 in combination with modified FOLFIRINOX for advanced pancreatic cancer, which is being conducted by SWOG.
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:39AM CDT
Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day.
SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer
PR Newswire - Thu Sep 18, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313). The trial is designed to evaluate Halozyme's investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma. The study will resume under a revised protocol, and patient enrollment is anticipated to recommence upon review and approval of the amended protocol by the Independent Review Boards at the participating clinical trial sites.
Nasdaq stocks posting largest percentage increases
AP - Wed Sep 17, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
5 Stocks With Big Insider Buying
at The Street - Wed Sep 17, 11:28AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
Biotech Stocks in Motion - XOMA, Nanosphere, Isis Pharma, Halozyme Therapeutics, and Synta Pharma
PR Newswire - Wed Sep 17, 7:45AM CDT
The US markets on Tuesday, September 16, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,131.97, up 0.59% and the NASDAQ Composite closed at 4,552.76, up 0.75%. The S&P 500 finished the session 0.75% higher at 1,998.98. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index gaining 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: XOMA Corporation (NASDAQ: XOMA), Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at:
Baxter and Halozyme Therapeutics Get FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 12:50PM CDT
Baxter International (BAX) expects to launch HYQVIA in the U.S. in a few weeks.
FDA Approves Baxter's HYQVIA for Treatment of Adu
M2 - Mon Sep 15, 10:10AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary Immunodeficiency
M2 - Mon Sep 15, 9:55AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
KRE, XME, XES, HALO, MLNX, GMM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 11, 4:27AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPDR S&P Regional Banking ETF (NYSE:KRE), Xmet Inc (NYSE:XME), SPDR S&P Oil & Gas Equipment & Services ETF (NYSE:XES), Halozyme Therapeutics Inc (NASDAQ:HALO), Mellanox Technologies Ltd (NASDAQ:MLNX), SPDR S&P Emerging Markets ETF (NYSE:GMM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Why You Shouldn't Bet Against Halozyme Therapeutics (HALO) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:42AM CDT
Halozyme Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
Halozyme's PEGPH20 Program Gains Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:00PM CDT
Earlier this week, Halozyme Therapeutics' (HALO) got some good news with the FDA granting fast track designation to the PEGPH20 (PEGylated recombinant human hyaluronidase) program.
Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation
PR Newswire - Wed Sep 03, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer to demonstrate an improvement in overall survival. The Fast Track designation process was developed by the FDA to facilitate the development, and expedite the review of drugs to treat serious or life-threatening diseases and address unmet medical needs.
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.
Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Pharma, Synta Pharma, Halozyme Therapeutics, and Isis Pharma
PR Newswire - Thu Aug 14, 8:30AM CDT
On Wednesday, August 13, 2014, the NASDAQ Composite ended at 4,434.13, up 1.02%, the Dow Jones Industrial Average finished the day 0.55% higher at 16,651.80, and the S&P 500 closed at 1,946.72, up 0.67%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.08, up 1.15%, with the index also advancing 4.55% in the previous three months. Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at:
Intercept Pharma Soars On Positive Liver Drug Data
at Investor's Business Daily - Mon Aug 11, 9:20PM CDT
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market...
Halozyme to Host second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Aug 04, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2014.
FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency
M2 - Mon Aug 04, 6:32AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.
